[144] Entegris Inc SEC Filing

Rhea-AI Filing Summary

The Form 144 for Entegris (ENTG) notifies a proposed sale of 8,858 shares of common stock through Fidelity Brokerage on NASDAQ with an aggregate market value of $707,222.72. The filing lists 151,600,000 shares outstanding, and the proposed approximate sale date is 08/13/2025.

The securities are shown as acquired via an option grant dated 02/05/2019, with acquisition and sale date entries of 08/13/2025, and payment described as cash. The form states there were no securities sold in the past three months and includes the standard signer representation that no material nonpublic adverse information is known and a note about Rule 10b5-1 trading plans.

Insights

Financial Analyst

TL;DR: Proposed sale of 8,858 shares valued at $707,222.72 appears immaterial to capitalization given the outstanding share count.

The filing discloses a planned disposition of 8,858 common shares with an aggregate market value of $707,222.72 scheduled for 08/13/2025. Relative to the stated 151,600,000 shares outstanding, the position represents approximately 0.0058% of outstanding shares, indicating limited direct impact on share supply or market capitalization. The shares are shown as acquired by option (grant dated 02/05/2019) and the transaction is routed through Fidelity on NASDAQ. No securities were reported sold in the prior three months.

Corporate Governance Expert

TL;DR: Form 144 follows disclosure and Rule 144 procedures and includes the required signer representation about material nonpublic information.

The notice contains the customary certifications required by Form 144, including the representation that the signer does not possess undisclosed material adverse information and a reference to Rule 10b5-1 trading plans. The filing specifies transaction mechanics (broker, exchange, payment method) and documents the option grant date used as the acquisition source. These elements align with standard compliance practices for proposed insider or affiliate sales under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	8858	707222.72	151600000	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/13/2025	Option Granted - 02/05/2019	Issuer			8858	08/13/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Entegris (ENTG) report in this Form 144?

The form reports a proposed sale of 8,858 common shares on 08/13/2025 with aggregate market value $707,222.72 via Fidelity on NASDAQ.

How were the shares acquired according to the filing?

The filing shows the shares were acquired via an option grant dated 02/05/2019, with the acquisition date listed as 08/13/2025.

Does the filing report recent sales by the same person?

The Form 144 states "Nothing to Report" under securities sold during the past three months.

Through which broker and exchange will the sale occur?

The proposed sale is listed through Fidelity Brokerage Services LLC and the securities exchange is NASDAQ.

What representations does the signer make on Form 144?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed and references Rule 10b5-1 plan adoption if applicable.